Molecular and Cellular Therapies (MCT) is a frontline journal for molecular mechanisms, preclinical and clinical research, and the development of gene-, peptide-, protein-, and cell-based therapies, which includes target identification and validation, safety, toxicity, efficacy, efficiency, pharmacokinetics, metabolism, formulation, delivery, pharmacovigilance, biomarkers, and new drug application. MCT is central to clinical and translational medicine and will integrate genetics, cell biology, medicine, drug development, therapeutics, and biotechnology to improve the prognosis of patients.

Aims and Scope

Molecular and Cellular Therapies is an online, open access journal which focuses on basic science and the clinical development of molecular and cell-based therapies.

The journal aligns basic research in the development of gene-, peptide-, protein-, and cell-based therapies with clinical and pre-clinical research, to establish new therapy parameters such as treatment pharmacokinetics, delivery, toxicity, efficacy, biomarkers and  novel applications.

In order to establish these parameters, Molecular and Cellular Therapies  welcomes research from a range of disciplines, including, but not limited to, genetics, cell biology, medicine, drug development, therapeutics and biotechnology.

The journal has four sections:

  • HIV pathogenesis and Treatment: Edited by Andrew Badley
  • Nanomedicine: Edited by Dan Peer
  • Regenerative Medicine and Therapies: Edited by Marek Malecki
  • Noncoding RNA Therapies: Edited by Ulf Andersson Ørom

Molecular and Cellular Therapies accepts research articles, reviews, commentaries, methodologies and short reports.